購物車 
-
N3-C5-NHS ester
- names：
N3-C5-NHS ester
- CAS號：
866363-70-4
MDL Number： MFCD25968077 - MF(分子式)： C10H14N4O4 MW(分子量)： 254.24
- EINECS: Reaxys Number:
- Pubchem ID:11594035 Brand:BIOFOUNT
N3-C5-NHS ester(866363-70-4)是一種不可降解 (non-cleavable) 的 ADC linker，N3-C5-NHS ester可用于合成抗體偶聯藥物 (ADCs)。
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM001026-500mg | 500mg | 98% | ￥ 14200.00 | ￥ 14200.00 | 2-3days | ￥ 0.00 | ||
| YZM001026-100mg | 100mg | 98% | ￥ 4680.00 | ￥ 4680.00 | 2-3days | ￥ 0.00 |
| 中文別名 | N3-C5-NHS ester(866363-70-4)疊氮-C5-琥珀酰亞胺酯;2,5-二氧雜吡咯烷-1-基6-疊氮己酸;N3-C5-NHS酯;2,5-吡咯烷二酮，1-[（（6-疊氮基-1-氧己基）氧基]-;己酸，6-疊氮基，2,5-二氧雜-1-吡咯烷基酯;SCHEMBL13946653;CTK3C6825;DTXSID10469149;AKOS037478135;CS-7066;6-疊氮己酸2,5-二氧吡咯并;DS-016314;HY-126523;CS-0105081;1-[（6-氮雜己基氧基）氧基]吡咯烷-2,5-二酮;A1-06739;6-疊氮基己酸2,5-二氧雜吡咯烷-1-基酯; |
| 英文別名 | N3-C5-NHS ester(866363-70-4);succinimidyl 6-azidohexanoate; 6-azidohexanoic acid N-hydroxysuccinimide ester; N-(6-azidohexanoyl)succinimide; 2,5-Pyrrolidinedione,1-[(6-azido-1-oxohexyl)oxy]; 6-azidohexanoic acid succinimidyl ester; 2,5-dioxopyrrolidin-1-yl 6-azidohexanoate; |
| CAS號 | 866363-70-4 |
| Inchi | InChI=1S/C10H14N4O4/c11-13-12-7-3-1-2-4-10(17)18-14-8(15)5-6-9(14)16/h1-7H2 |
| InchiKey | FVWGCTQOFSJEDB-UHFFFAOYSA-N |
| 分子式 Formula | C10H14N4O4 |
| 分子量 Molecular Weight | 254.24 |
| 溶解度Solubility | |
| 性狀 | Solid |
| 儲藏條件 Storage conditions | 請根據產品建議的存儲條件進行存儲,Please store the product under the recommended condition sin the description. |
N3-C5-NHS ester(866363-70-4)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:N3-C5-NHS ester試劑,N3-C5-NHS ester雜質,N3-C5-NHS ester密度,N3-C5-NHS ester溶解度,N3-C5-NHS ester旋光度,N3-C5-NHS ester閃點,N3-C5-NHS ester熔點,N3-C5-NHS ester結構式,N3-C5-NHS ester購買,
| 產品說明 | N3-C5-NHS ester(866363-70-4)是一種不可降解 (non-cleavable) 的 ADC linker,可用于合成抗體偶聯藥物 (ADCs) |
| Introduction | N35HS ester(866363-70-4) is a noncleavable ADC linker used in the synthesis of antibodyrug conjugates (ADCs). |
| Application1 | |
| Application2 | |
| Application3 |
N3-C5-NHS ester(866363-70-4)藥理學：
N3-C5-NHS ester(866363-70-4)是一種不可降解 (non-cleavable) 的 ADC linker，N3-C5-NHS ester可用于合成抗體偶聯藥物 (ADCs)。
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護 | P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理 |
| 備注 | 實驗過程中防止吸入、食入，做好安全防護 |
| Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers. J Med Chem. 2017 Dec 14;60(23):9490-9507. |
N3-C5-NHS ester(866363-70-4)參考文獻：
1、Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers
Stephen J Gregson 1, Luke A Masterson 1, Binqing Wei 2, Thomas H Pillow 2, Susan D Spencer 2, Gyoung-Dong Kang 1, Shang-Fan Yu 2, Helga Raab 2, Jeffrey Lau 2, Guangmin Li 2, Gail D Lewis Phillips 2, Janet Gunzner-Toste 2, Brian S Safina 2, Rachana Ohri 2, Martine Darwish 2, Katherine R Kozak 2, Josefa Dela Cruz-Chuh 2, Andrew Polson 2, John A Flygare 2, Philip W Howard
Abstract Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate 19 for use in antibody-drug conjugates (ADCs). They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne (6), triazole (7), or piperazine (8) link to the PBD. In vitro IC50 values were 11-48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (7 inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10-1.73 μg/mL (7 inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses). In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was observed with tumor stasis at 0.5-1 mg/kg, 1 mg/kg, and 3-6 mg/kg for 6, 8, and 7, respectively. Tumor stasis at 2 mg/kg was observed for anti-CD22 6 in WSU-DLCL2. In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.
1、Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers
Stephen J Gregson 1, Luke A Masterson 1, Binqing Wei 2, Thomas H Pillow 2, Susan D Spencer 2, Gyoung-Dong Kang 1, Shang-Fan Yu 2, Helga Raab 2, Jeffrey Lau 2, Guangmin Li 2, Gail D Lewis Phillips 2, Janet Gunzner-Toste 2, Brian S Safina 2, Rachana Ohri 2, Martine Darwish 2, Katherine R Kozak 2, Josefa Dela Cruz-Chuh 2, Andrew Polson 2, John A Flygare 2, Philip W Howard
Abstract Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate 19 for use in antibody-drug conjugates (ADCs). They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne (6), triazole (7), or piperazine (8) link to the PBD. In vitro IC50 values were 11-48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (7 inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10-1.73 μg/mL (7 inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses). In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was observed with tumor stasis at 0.5-1 mg/kg, 1 mg/kg, and 3-6 mg/kg for 6, 8, and 7, respectively. Tumor stasis at 2 mg/kg was observed for anti-CD22 6 in WSU-DLCL2. In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.
對不起，暫無產品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養耗材技術領先性
細胞培養板行業面臨的核心痛點是：常規TC處理后表面親水角隨時間衰減，影響長期培養穩定性，BIOFOUNT高分...
2026/4/28 15:12:51
細胞培養耗材關鍵性能
細胞培養板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環節，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
